• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BMI1 将 CML B 淋巴样祖细胞重编程为 B-ALL 起始细胞。

Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells.

机构信息

Stem Cell Program, Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, OH, USA.

出版信息

Blood. 2012 Jan 12;119(2):494-502. doi: 10.1182/blood-2011-06-359232. Epub 2011 Nov 18.

DOI:10.1182/blood-2011-06-359232
PMID:22101899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3257014/
Abstract

The characterization and targeting of Philadelphia chromosome positive (Ph(+)) acute lymphoblastic leukemia (ALL)-initiating cells remains unresolved. Expression of the polycomb protein Bmi1 is up-regulated in patients with advanced stages of chronic myelogenous leukemia (CML). We report that Bmi1 transforms and reprograms CML B-lymphoid progenitors into stem cell leukemia (Scl) promoter-driven, self-renewing, leukemia-initiating cells to result in B-lymphoid leukemia (B-ALL) in vivo. In vitro, highly proliferating and serially replatable myeloid and lymphoid colony-forming cultures could be established from BCR-ABL and Bmi1 coexpressing progenitors. However, unlike in vivo expanded CML B-lymphoid progenitors, hematopoietic stem cells, or multipotent progenitors, coexpressing BCR-ABL and Bmi1 did not initiate or propagate leukemia in a limiting dilution assay. Inducible genetic attenuation of BCR-ABL reversed Bmi1-driven B-ALL development, which was accompanied by induction of apoptosis of leukemic B-lymphoid progenitors and by long-term animal survival, suggesting that BCR-ABL is required to maintain B-ALL and that BCR-ABL and Bmi1 cooperate toward blast transformation in vivo. Our data indicate that BCR-ABL targeting itself is required to eradicate Ph(+)/Bmi1(+) B-ALL-initiating cells and confirm their addiction to BCR-ABL signaling.

摘要

费城染色体阳性(Ph(+))急性淋巴细胞白血病(ALL)起始细胞的特征和靶向仍然未得到解决。多梳蛋白 Bmi1 的表达在慢性粒细胞白血病(CML)的晚期患者中上调。我们报告称,Bmi1 可将 CML B 淋巴细胞祖细胞转化并重新编程为干细胞白血病(Scl)启动子驱动的、自我更新的、起始细胞,从而导致体内 B 淋巴细胞白血病(B-ALL)。在体外,从共表达 BCR-ABL 和 Bmi1 的祖细胞中可以建立高度增殖和可连续复制的髓样和淋巴样集落形成培养物。然而,与体内扩增的 CML B 淋巴细胞祖细胞、造血干细胞或多能祖细胞不同,共表达 BCR-ABL 和 Bmi1 的细胞在有限稀释测定中不会起始或传播白血病。BCR-ABL 的可诱导遗传衰减逆转了 Bmi1 驱动的 B-ALL 发展,伴随着白血病 B 淋巴细胞祖细胞的凋亡诱导和长期动物存活,表明 BCR-ABL 是维持 B-ALL 所必需的,并且 BCR-ABL 和 Bmi1 在体内合作进行原始细胞转化。我们的数据表明,BCR-ABL 靶向本身是根除 Ph(+)/Bmi1(+) B-ALL 起始细胞所必需的,并证实它们依赖于 BCR-ABL 信号。

相似文献

1
Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells.BMI1 将 CML B 淋巴样祖细胞重编程为 B-ALL 起始细胞。
Blood. 2012 Jan 12;119(2):494-502. doi: 10.1182/blood-2011-06-359232. Epub 2011 Nov 18.
2
BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells.BMI1 与 BCR-ABL 协同作用于人类 CD34+ 细胞的白血病转化。
Blood. 2010 Nov 25;116(22):4621-30. doi: 10.1182/blood-2010-02-270660. Epub 2010 Aug 19.
3
Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo.Rac2 GTPase 缺陷在体内耗尽 BCR-ABL+白血病干细胞和祖细胞。
Blood. 2010 Jul 8;116(1):81-4. doi: 10.1182/blood-2009-10-247437. Epub 2010 Apr 20.
4
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.慢性髓性白血病干细胞的存活不依赖于 Bcr-Abl 激酶活性。
Blood. 2012 Feb 9;119(6):1501-10. doi: 10.1182/blood-2010-12-326843. Epub 2011 Dec 19.
5
Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.Gadd45a基因缺陷会加速BCR-ABL驱动的慢性粒细胞白血病进程。
Oncotarget. 2017 Feb 14;8(7):10809-10821. doi: 10.18632/oncotarget.14580.
6
Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.慢性粒细胞白血病患者经酪氨酸激酶抑制剂金雀异黄素体外处理后,选择缺乏BCR/ABL mRNA的髓系祖细胞。
Blood. 1996 Oct 15;88(8):3091-100.
7
Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.BCR-ABL-Y177 介导的 p27kip1 磷酸化和细胞质定位在慢性髓性白血病祖细胞增殖中的作用。
Leukemia. 2010 Apr;24(4):779-87. doi: 10.1038/leu.2010.24. Epub 2010 Mar 4.
8
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.粒-巨噬细胞祖细胞作为急变期慢性粒细胞白血病中候选白血病干细胞
N Engl J Med. 2004 Aug 12;351(7):657-67. doi: 10.1056/NEJMoa040258.
9
c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells.c-Myb 和其靶基因 Bmi1 对于小鼠和人细胞中 p190BCR/ABL 白血病的发生是必需的。
Leukemia. 2012 Apr;26(4):644-53. doi: 10.1038/leu.2011.264. Epub 2011 Sep 30.
10
Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.奥马西他辛对小鼠白血病干细胞以及BCR-ABL诱导的慢性髓性白血病和急性淋巴细胞白血病的抑制作用。
Leukemia. 2009 Aug;23(8):1446-54. doi: 10.1038/leu.2009.52. Epub 2009 Mar 26.

引用本文的文献

1
Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis.核 Vav3 在 B 细胞淋巴母细胞白血病发生中多梳抑制复合物-1 活性所必需的。
Nat Commun. 2022 Jun 1;13(1):3056. doi: 10.1038/s41467-022-30651-7.
2
Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers.整合遗传和表观遗传因素在慢性髓性白血病风险评估中的作用:基于基因表达的生物标志物。
Haematologica. 2022 Feb 1;107(2):358-370. doi: 10.3324/haematol.2021.279317.
3
Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML.慢性粒细胞白血病中的表观遗传重编程与新兴的表观遗传疗法
Front Cell Dev Biol. 2019 Jul 17;7:136. doi: 10.3389/fcell.2019.00136. eCollection 2019.
4
Effects of leaf extract on lipopolysaccharide -induced neuroinflammation in rats: A behavioral and H NMR-based metabolomics study.叶提取物对大鼠脂多糖诱导的神经炎症的影响:一项基于行为学和核磁共振氢谱代谢组学的研究
Avicenna J Phytomed. 2019 Mar-Apr;9(2):164-186.
5
is a recurrent fusion gene partner in B-cell precursor acute lymphoblastic leukemia associated with increased expression of genes on chromosome band 10p12.31-12.2.是B细胞前体急性淋巴细胞白血病中一种反复出现的融合基因伙伴,与染色体带10p12.31 - 12.2上基因的表达增加相关。
Haematologica. 2019 Oct;104(10):e455-e459. doi: 10.3324/haematol.2018.206961. Epub 2019 Mar 14.
6
The signaling axis atypical protein kinase C λ/ι-Satb2 mediates leukemic transformation of B-cell progenitors.非典型蛋白激酶 C λ/ι-Satb2 信号轴介导 B 细胞祖细胞的白血病转化。
Nat Commun. 2019 Jan 4;10(1):46. doi: 10.1038/s41467-018-07846-y.
7
Stat5 deficiency decreases transcriptional heterogeneity and supports emergence of hematopoietic sub-populations.Stat5缺陷降低转录异质性并支持造血亚群的出现。
Oncotarget. 2017 Apr 4;8(14):22477-22482. doi: 10.18632/oncotarget.15236.
8
Modeling of Chronic Myeloid Leukemia: An Overview of In Vivo Murine and Human Xenograft Models.慢性髓性白血病的建模:体内小鼠和人异种移植模型概述
Stem Cells Int. 2016;2016:1625015. doi: 10.1155/2016/1625015. Epub 2016 Aug 25.
9
BMI1: A Biomarker of Hematologic Malignancies.BMI1:血液系统恶性肿瘤的生物标志物。
Biomark Cancer. 2016 May 5;8:65-75. doi: 10.4137/BIC.S33376. eCollection 2016.
10
Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.在基于人骨髓样支架的异种移植模型中模拟 BCR-ABL 和 MLL-AF9 白血病。
Leukemia. 2016 Oct;30(10):2064-2073. doi: 10.1038/leu.2016.108. Epub 2016 Apr 29.

本文引用的文献

1
Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives.费城染色体阳性急性淋巴细胞白血病:当前的治疗方法和未来展望。
Cancer. 2011 Apr 15;117(8):1583-94. doi: 10.1002/cncr.25690. Epub 2010 Nov 8.
2
CREBBP mutations in relapsed acute lymphoblastic leukaemia.复发急性淋巴细胞白血病中的 CREBBP 突变。
Nature. 2011 Mar 10;471(7337):235-9. doi: 10.1038/nature09727.
3
Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors.酪氨酸激酶抑制剂时代费城阳性 B 淋巴细胞白血病免疫表型和核型特征的预后意义。
Cancer. 2011 Sep 1;117(17):4009-17. doi: 10.1002/cncr.25978. Epub 2011 Mar 1.
4
Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells.人类 BCR-ABL1 淋巴母细胞白血病起始细胞的演变。
Nature. 2011 Jan 20;469(7330):362-7. doi: 10.1038/nature09733.
5
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.尽管抑制了 BCR-ABL 活性,但人类慢性髓系白血病干细胞对伊马替尼不敏感。
J Clin Invest. 2011 Jan;121(1):396-409. doi: 10.1172/JCI35721. Epub 2010 Dec 13.
6
BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells.BMI1 与 BCR-ABL 协同作用于人类 CD34+ 细胞的白血病转化。
Blood. 2010 Nov 25;116(22):4621-30. doi: 10.1182/blood-2010-02-270660. Epub 2010 Aug 19.
7
Chronic myeloid leukemia: mechanisms of blastic transformation.慢性髓细胞白血病:细胞性白血病转化的机制。
J Clin Invest. 2010 Jul;120(7):2254-64. doi: 10.1172/JCI41246. Epub 2010 Jul 1.
8
Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.组蛋白去乙酰化酶抑制剂联合甲磺酸伊马替尼靶向静止期慢性髓系白血病干细胞的作用。
Cancer Cell. 2010 May 18;17(5):427-42. doi: 10.1016/j.ccr.2010.03.011.
9
Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo.Rac2 GTPase 缺陷在体内耗尽 BCR-ABL+白血病干细胞和祖细胞。
Blood. 2010 Jul 8;116(1):81-4. doi: 10.1182/blood-2009-10-247437. Epub 2010 Apr 20.
10
Poised lineage specification in multipotential hematopoietic stem and progenitor cells by the polycomb protein Bmi1.多能造血干/祖细胞中多梳蛋白 BMI1 对细胞定型的调控作用。
Cell Stem Cell. 2010 Mar 5;6(3):279-86. doi: 10.1016/j.stem.2010.01.005.